Akers biosciences, inc. (AKER)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net Loss

-3,538

-1,339

-837

-794

-916

-3,837

-3,083

-2,067

-1,859

-4,021

-1,177

-818

-1,349

-1,095

310

-1,008

-1,508

-

-

-

-

-

-

-

-595

-781

-544

-261

60

Net loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,321

-

-

-

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Loss on sale of securities

-36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued (income)/loss on marketable securities

4

2

-2

-1

-2

0

-5

2

13

1

-0

0

0

-0

-4

0

-9

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

15

19

19

19

15

61

60

56

56

67

61

60

60

64

108

57

56

58

80

80

80

87

87

86

86

88

89

88

88

Impairment of intangible assets

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reserve for obsolete inventory

3

-

-

-

-

60

186

7

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reserve and write-off for obsolete inventory

-

-

-

-

-

-

-

-

-

-

-

53

-32

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reserve for obsolete inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest and dividends on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7

6

-3

15

0

-

-

-

-

Reserve for doubtful trade receivables

-

-100

101

0

4

-

-

-

-

-

-

-

40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Allowance for doubtful accounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain from other non-operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5

0

0

9

-4

-

-

-

-

Amortization of deferred compensation

-

-

-

-

-

0

0

0

3

5

-0

10

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation to employees - options

-

-

-

-

-

0

1

2

2

2

4

5

5

5

22

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation to an employee - common stock

-

-

-

10

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation to directors - restricted stock units

1

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of restricted common stock issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain from demutualization of insurer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

91

Share based compensation - shares issued to vendors

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for the purchase of license

1,233

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation to an employees - restricted stock

-

-

-

-

-

-

0

0

5

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation to non-employees - options

-

-

-

-

-

-

-

-

-

-

-

-

-

0

15

0

8

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation to non-employees - restricted stock

-

-

-

-

-

-

0

0

12

-

5

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in assets and liabilities
Increase in trade receivables

278

-188

-34

-57

152

-47

-129

92

-547

211

197

415

-43

-137

195

-92

172

-468

-792

767

-20

941

31

906

20

45

-90

67

-4

Decrease in trade receivables - related party

-

-

-

-

-

-

-

-

-

-

0

-24

-7

0

0

0

0

-

-

-

-

-

0

0

266

168

0

123

908

Decrease in notes receivables - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-44

-88

-43

266

0

0

0

-

-

-

-

Decrease in deposits and other receivables

0

0

0

0

-9

-51

0

-2

46

-5

8

0

-10

-5

-34

14

-46

-5

67

7

-14

-18

42

-17

30

-22

0

0

21

Increase in deposit and other receivables - related party

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in license fees receivable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-450

(Increase)/Decrease in inventories

-1

32

-5

-57

16

-162

-20

48

50

-231

-102

112

100

126

-24

5

80

176

133

-147

64

117

32

87

-359

-59

217

-45

-74

Decrease in prepaid expenses

-47

-85

287

-122

-182

-121

-174

445

76

-55

-48

49

-69

74

-47

3

-47

16

-7

47

20

-

-

-

-

-

-

-

-

Decrease in prepaid expenses - related party

-

-

-

-

-

-

-

-

-

-

8

-30

-16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in prepaid expenses - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

-35

56

-118

50

83

-22

-15

Increase in trade and other payables

504

156

-244

-462

107

-327

449

472

-405

-86

135

238

-200

213

-315

22

-125

412

91

236

87

872

27

28

-390

138

-119

24

72

Increase in operating lease liability

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase/(decrease) in trade and other payables - related party

-

-

-

-

-

-

-

-

-

-

-13

-61

-138

174

59

0

0

-

-

-

-

0

0

0

-6

-42

49

-26

-32

Decrease in legal settlement liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-25

-32

-48

Increase in deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-222

-83

-83

-83

-83

-83

-83

-83

-83

-83

Net cash used by operating activities

-1,966

-501

-962

-861

-748

-2,638

-2,045

-2,017

-1,800

-1,425

-1,061

-1,031

-1,561

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,719

-1,131

-1,036

-1,721

-1,241

-1,126

-962

-962

-832

-861

-843

-604

-420

Cash flows from investing activities:
Purchases of property, plant and equipment

-

-

-

-

-

0

30

-0

37

17

0

20

16

35

6

-2

83

52

15

-0

44

0

23

1

0

23

28

63

7

Purchases of marketable securities

41

6,617

24

32

30

1,283

52

1,296

3,972

5,000

3

1,502

1,202

-1

9

8

19

8

17

7

27

13

23

4

12,508

0

0

0

0

Investment in Hainan Savy Akers Biosciences, Ltd. joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

64

0

0

0

0

-

-

-

-

Proceeds from other non-operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5

-

-

-

-

-

-

-

-

Proceeds from demutualization of insurance carrier

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4

0

0

0

91

Proceeds from other non-operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Proceeds from sale of marketable securities

2,303

301

1,201

502

852

852

3,153

2,004

302

0

1,003

650

1,095

550

950

900

1,601

1,201

1,202

1,652

1,253

953

1,249

1,081

0

-

-

-

-

Net cash provided by investing activities

2,261

-6,309

1,077

469

822

-430

3,070

708

-3,708

-5,017

999

-873

-123

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided/(consumed) by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,498

1,140

1,168

1,646

1,122

939

1,202

1,074

-12,504

-23

-28

36

83

Cash flows from financing activities
Proceeds from note receivable - related party for Series A Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

225

Payment of short-term note payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

307

-307

0

0

0

Proceeds from other receivable for London Private Placement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

2,390

0

-39

3,452

0

0

0

0

-

-

-

-

0

0

0

745

-

-

-

-

Net proceeds from the exercise of prepaid equity forward contracts for the purchase of common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from exercise of warrants for common stock

-

-

-

-

-

0

0

1,437

5,717

680

0

56

244

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

0

-

-

-

-

1,950

0

1,437

5,717

6,746

0

16

3,697

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and restricted cash

294

154

114

-391

73

-1,119

1,025

128

208

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock in initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

13,101

0

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-15

13,538

307

0

1,600

225

Net increase/(decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

2,012

-123

-183

199

-221

8

132

-75

-119

-186

240

96

202

-577

-872

1,032

-111

Supplemental cash flow information:
Supplemental Schedule of Non-Cash Financing and Investing Activities
Net unrealized gains/(losses) on marketable securities

-240

-1

-1

18

29

-20

6

4

-16

-

-1

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use asset obtained in exchange for lease obligation

306

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series B Preferred Stock to common shares

-

-

-

-

-

0

0

0

1,755

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of a restricted common stock grant for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net unrealized gains on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-2

-2

8

-

-

-

-

-

-

-

-

-

-

-

-

Net unrealized gains on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15

5

-3

26

-8

-8

7

-10

0

0

0

0

Issuance of restricted common share grants to directors and officers accrued in 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

697

0

0

0

0

-

-

-

-